Vertaling van "agreement to acquire " (Nederlands → Frans) :

TERMINOLOGIE

CAP - community acquired pneumonie
pneumonie acquise dans la collectivité

acquired immunodeficiency syndrome [AIDS] NNO | AIDS-related complex [ARC] NNO
Complexe relatif au SIDA [ARC] SAI Syndrome d'immunodéficience acquise [SIDA] SAI

IN-CONTEXT TRANSLATIONS

In 2009 Novartis announced an agreement to acquire an 85% stake in the Chinese vaccines company Zhejiang Tianyuan Bio-Pharmaceuticals Co., Ltd.
Novartis a annoncé, en 2009, avoir signé un accord pour acquérir une participation de 85% dans la société Zhejiang Tianyuan Bio-Pharmaceuticals Co., Ltd., qui fabrique des vaccins en Chine.

Vaccines and Diagnostics – Zhejiang Tianyuan On November 4, Novartis announced a definitive agreement to acquire an 85% stake in the Chinese vaccines company Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.
Vaccins et Diagnostic – Zhejiang Tianyuan Le 4 novembre, Novartis a annoncé un accord définitif pour acquérir une participation de 85% dans Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd., une société chinoise qui fabrique des vaccins.

Under the terms of the agreement, Novartis acquired a 25% Alcon stake from Nestlé in 2008 for USD 10.4 billion, or USD 143 per share.
Selon les termes de cet accord, Novartis a acquis en 2008 de Nestlé une part de 25% dans Alcon pour USD 10,4 milliards, soit USD 143 par action.

Novartis announced on January 4 plans to gain full ownership of Alcon by first completing the agreement to acquire a 77% majority stake – on track for completion in the second half of 2010 – and subsequently entering into an all-share direct merger with Alcon for the remaining 23% minority stake.
Novartis a annoncé, le 4 janvier, son intention d’obtenir la propriété pleine et entière d’Alcon en finalisant d’abord l’accord en vue d’acquérir une participation majoritaire de 77% – cette transaction devrait se terminer au second semestre 2010. Puis, Novartis entamera une fusion-absorption de la participation minoritaire restante de 23%.

Pharmaceuticals – Corthera On December 23, Novartis announced a definitive agreement to acquire Corthera Inc, gaining worldwide rights to relaxin for the treatment of acute heart failure.
Pharmaceuticals – Corthera Le 23 décembre, Novartis a annoncé un accord définitif pour acquérir Corthera Inc, obtenant ainsi les droits dans le monde entier de relaxine pour traiter l'insuffisance cardiaque aiguë.

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

Corporate – Alcon On April 7, Novartis announced an agreement with Nestlé S.A. under which Novartis obtained rights to acquire in two steps majority ownership of Alcon Inc (NYSE: ACL), a Swiss-registered company listed only on the New York Stock Exchange.
Corporate – Alcon Le 7 avril, Novartis a annoncé avoir conclu un accord avec Nestlé S.A. lui donnant le droit d’acquérir, en deux étapes, une participation majoritaire dans Alcon Inc (NYSE: ACL), une société enregistrée en Suisse mais cotée uniquement à la Bourse de New York.

Sandoz – EBEWE Pharma On May 20, Novartis announced a definitive agreement for Sandoz to acquire the specialty generic injectables business of EBEWE Pharma for EUR 925 million (USD 1.3 billion) in cash, to be adjusted for any cash or debt assumed at closing.
Sandoz – EBEWE Pharma Le 20 mai, Novartis a annoncé avoir conclu un accord définitif portant sur l’acquisition par Sandoz du domaine thérapeutique des spécialités génériques injectables d’EBEWE Pharma pour EUR 925 millions (USD 1,3 milliard) en espèces, montant qui sera ajusté des liquidités ou des dettes estimées à la date de clôture.